The Impact Of ABSORB II: Down The Slippery Slope

When it was approved earlier this year in July the Absorb (Abbott) bioresorbable stent provoked a fair amount of discussion about the “slippery slope of noninferiority.” Although the stent met the FDA criteria for approval, the available trial results went in the wrong direction and there was a particularly concerning warning sign of a higher...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Abbott ABSORB bioresorbable stent FDA noninferiority postapproval stents Source Type: blogs